Clinical and Molecular Hepatology

Article	Citations
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma	358
Reply to correspondence on “Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis”	294
Unveiling the Intratumor Microbiome in Liver Cancer: Current Insights and Prospective Applications	216
Correspondence to editorial on “Integrated Molecular Characterization of Sarcomatoid Hepatocellular Carcinoma”	195
Reply to correspondence on “The Burden of Steatotic Liver Disease before and during the COVID Pandemic”	186
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	154
Reply to correspondence to editorial on “Bariatric Surgery Reduces Long-Term Mortality in Patients with MASLD and Cirrhosis”	102
Deciphering adenosine signaling in hepatocellular carcinoma: pathways, prognostic models, and therapeutic implications	94
TM4SF1 - A new immune target for treatment of hepatocellular carcinoma	74
Baveno VI-SSM was able to stratify the risk of portal hypertension-related events in patients with HBV-related cirrhosis	74
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”	72
TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure?	70
KASL clinical practice guidelines for management of autoimmune hepatitis 2022	67
Another oral antiviral treatment, but still far away from hepatitis B virus cure	65
Microbiome and metabolomics in alcoholic liver disease	65
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B	64
Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: a nonnegligible risk to liver-related health	61
Correspondence to “Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer”	59
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”	57
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	51
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues	50
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”	49
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”	48
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China	48
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	45

Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	45
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”	45
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”	43
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments	41
Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”	41
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	39
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”	39
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”	39
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	39
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”	38
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	37
Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”	35
Critical Considerations in Evaluating the Therapeutic Potential of HK-660S for Primary Sclerosing Cholangitis	34
Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study	34
Regulation of Hepatitis B Virus cccDNA by Metabolic Pathways	34
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers	34
Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications	33
Prediction and prevention of post-procedural bleedings in patients with cirrhosis	33
Vibration-Controlled Transient Elastography in Shaping the Epidemiology and Management of Steatotic Liver Disease	32
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD	32
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations	31
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	31
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	31
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antiv	30
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization	30
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	30
Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”	30
Adding to the confusion in more than just the name	30
Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”	30
Correspondence to editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”	29
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	29
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research	29
Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with earl	28
Nucleos(t)ide analog therapy of chronic hepatitis B and extrahepatic cancer risk: Is tenofovir better than entecavir?: Editorial on “Extrahepatic malignancies and antiviral drugs for chronic hepatitis	28
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances	28
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	27
Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease p	27
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	26
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	26
Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepati	25
Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis	25
Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK	24
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	24
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes	23
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?	23
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	23
Approaches to quantifying hepatitis B virus covalently closed circular DNA	23
Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma	23
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	22
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?	22

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review	22
Current status and outcome of liver transplantation in South Korea	22
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hep	21
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective	21
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial	21
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study	20
Surveillance for hepatocellular carcinoma: It is time to move forward	20
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	20
Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”	19
The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus	19
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease	19
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	19
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations	19
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease	19
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management	19
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	18
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology	18
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	18
The role of the hepatic autonomic nervous system	18
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?	18
Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	18
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	18
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	17
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	17
Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection	17
Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive	17
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	17
Erratum to ‘Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”’ [Clin Mol Hepatol 2023;29:1048-1049]	17
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma	16
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease	16
Preface	16
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases	16
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods	15
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?	15
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	15
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study	15
Changes in the epidemiology and management of bacterial infections in cirrhosis	15
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	15
Screening strategy for non-alcoholic fatty liver disease	15
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future	14
Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”	14
Anti-fibrotic treatments for chronic liver diseases: The present and the future	14
MARC1 downregulation reduces hepatocyte lipid content by increasing beta-oxidation	14
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	14
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective	14
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	14
Prospect of emerging treatments for hepatitis B virus functional cure	13
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection	13
Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment	13
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region	12
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis	12
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma	12
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus	12
Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome	11
Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	11
Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	11
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls	11
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis	11
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	11
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis	11
KASL clinical practice guidelines for management of chronic hepatitis B	11
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma	11
Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	10
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”	10
Erratum to ‘History and future of hepatitis B virus control in South Korea’ [Clin Mol Hepatol 2021;27:620-622]	10
The growing burden of non-alcoholic fatty liver disease on mortality	10
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases	10
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”	10
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	10
Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”	10
Acute on chronic liver failure in cirrhosis	10
Letter regarding “Evidence-based hyponatremia management in liver disease”	9
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B	9
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective	9
Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis	9
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	9
Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis	9
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study	9
Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia	9
JCAD, a new potential therapeutic target in cholestatic liver disease	9

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy	8
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	8
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply	8
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fat	8
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	8
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets	8
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study	8
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	8
Toward hepatitis C virus elimination using artificial intelligence	8
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	8